Literature DB >> 12443783

Reductively activated disulfide prodrugs of paclitaxel.

Vivekananda M Vrudhula1, John F MacMaster, Zhengong Li, David E Kerr, Peter D Senter.   

Abstract

A series of unsymmetrical polar disulfide prodrugs 2-5 of paclitaxel were designed and synthesized as reductively activated prodrugs. These compounds behaved as prodrugs in vitro on L2987 lung carcinoma cells. In vivo evaluation in mice demonstrated that the mutual prodrug 5 with captopril exhibited significant regressions and cures.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12443783     DOI： 10.1016/s0960-894x(02)00784-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  9 in total

1.  Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct.

Authors:  Su-Tang Lo; Stephan Stern; Jeffrey D Clogston; Jiwen Zheng; Pavan P Adiseshaiah; Marina Dobrovolskaia; Jongdoo Lim; Anil K Patri; Xiankai Sun; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action.

Authors:  Erika N Cline; Ming-Hsin Li; Seok Ki Choi; Jeffrey F Herbstman; Neha Kaul; Edgar Meyhöfer; Georgios Skiniotis; James R Baker; Ronald G Larson; Nils G Walter
Journal:  Biomacromolecules       Date:  2013-02-21       Impact factor: 6.988

Review 3.  Improved biochemical strategies for targeted delivery of taxoids.

Authors:  Thota Ganesh
Journal:  Bioorg Med Chem       Date:  2007-03-18       Impact factor: 3.641

4.  Evaluation of a reducible disulfide linker for siderophore-mediated delivery of antibiotics.

Authors:  Wilma Neumann; Elizabeth M Nolan
Journal:  J Biol Inorg Chem       Date:  2018-07-02       Impact factor: 3.358

5.  Cyclic 5-membered disulfides are not selective substrates of thioredoxin reductase, but are opened nonspecifically.

Authors:  Jan G Felber; Lena Poczka; Karoline C Scholzen; Lukas Zeisel; Martin S Maier; Sander Busker; Ulrike Theisen; Christina Brandstädter; Katja Becker; Elias S J Arnér; Julia Thorn-Seshold; Oliver Thorn-Seshold
Journal:  Nat Commun       Date:  2022-04-01       Impact factor: 14.919

6.  Convenient and efficient synthesis of functionalized unsymmetrical Z-alkenyl disulfanes.

Authors:  M Musiejuk; J Doroszuk; D Witt
Journal:  RSC Adv       Date:  2018-03-07       Impact factor: 3.361

Review 7.  Prodrug Strategies for Paclitaxel.

Authors:  Ziyuan Meng; Quanxia Lv; Jun Lu; Houzong Yao; Xiaoqing Lv; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

8.  The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.

Authors:  Ping Song; Xin Yao; Ting Zhong; Shuang Zhang; Yang Guo; Wei Ren; Dan Huang; Xiao-Chuan Duan; Yi-Fan Yin; Shu-Shi Zhang; Xuan Zhang
Journal:  Oncotarget       Date:  2016-07-26

9.  Phosphorus-Sulfur Heterocycles Incorporating an O-P(S)-O or O-P(S)-S-S-P(S)-O Scaffold: One-Pot Synthesis and Crystal Structure Study.

Authors:  Guoxiong Hua; Kate Davidson; David B Cordes; Junyi Du; Alexandra M Z Slawin; J Derek Woollins
Journal:  Molecules       Date:  2017-10-10       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.